Tech Company Financing Transactions
ImmuneXcite Funding Round
ImmuneXcite, based in Lexington, secured $8.6 million from Cormorant Asset Management, Partners Innovation Fund and Sanofi-Genzyme BioVentures.
Transaction Overview
Company Name
Announced On
12/11/2015
Transaction Type
Venture Equity
Amount
$8,600,000
Round
Series A
Investors
Proceeds Purpose
ImmuneXcite plans to use the funding to complete studies that will enable selection of a lead program to advance into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Forbes Rd.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
The mAbXcite platform is ImmuneXcite's proprietary product-focused drug discovery engine that represents a fundamentally new approach in the rapidly growing field of cancer immunotherapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Furfine
Chief Scientific Officer
Ifat Rubin-Bejerano
Browse more venture capital transactions:
Prev: 12/11/2015: The Tab venture capital transaction
Next: 12/11/2015: Rhythm Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs